EUVIMEDExplore EUVIMED
Open access · CC BY-NC-ND 4.0

A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents

Rochelle Woodland iD, Adi Suwandi iD, Awgichew Behaile Teklemariam iD, Nidhish Francis iD, Li Li iD, Kenneth A Chinkwo iD, Jonathan B Baell iD, David J Leaver iD

ChemMedChem · 2026-10-28 · 21 (20)

DOI: 10.1002/cmdc.70534 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-10-22. Written by Rochelle Woodland and 7 co-authors. Institution: School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia. Major MEDLINE topics: Antineoplastic Agents, Enzyme Inhibitors, Histone Acetyltransferases. 51 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: The National Health and Medical Research Council of Australia.

AbstractSubjectsBibliographic detailsCiteRelated studies

Abstract (original language)

The development of lysine acetyltransferase (KAT) inhibitors as anticancer agents has progressed rapidly from initial tool compounds to numerous molecules entering clinical trials. The most clinically advanced KAT6A inhibitor, prifetrastat (PF‐07248144), entered Phase III clinical trials in 2025. The discovery of prifetrastat is an excellent example of instrumental contributions made by Australian biomedical and medicinal chemistry researchers to the creation of innovative and cutting‐edge anticancer therapeutics. Within this perspective we summarize KAT6A structural biology and structure–activity relationships (SAR) for acylsulfonylhydrazides, [1,2,4]thiadiazines and benzisoxazole sulfonamide inhibitors in addition to providing updates on KAT6A inhibitors that have already entered into clinical trials. Key clinical challenges and opportunities facing the field are discussed herein.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsEnzyme InhibitorsHistone AcetyltransferasesHumansMolecular StructureStructure-Activity Relationship

Author keywords

clinical triallysine acetyltransferasesstructural biology

Substances

Antineoplastic AgentsEnzyme InhibitorsHistone AcetyltransferasesKAT6A protein, human

Authors and institutions

  • School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
  • Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Gulbali Institute, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
  • Manas AI, New York, New York, USA.
  • Department of Chemistry and Biochemistry, Lubbock Christian University, Lubbock, Texas, USA.

ORCID profiles: Rochelle Woodland, Adi Suwandi, Awgichew Behaile Teklemariam, Nidhish Francis, Li Li, Kenneth A Chinkwo, Jonathan B Baell, David J Leaver

Funding

  • The National Health and Medical Research Council of Australia

Cite

APA

Woodland, R., Suwandi, A., Teklemariam, A. B., Francis, N., Li, L., Chinkwo, K. A., Baell, J. B., & Leaver, D. J. (2026). A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents. ChemMedChem, 21(20). https://doi.org/10.1002/cmdc.70534

Vancouver

Woodland R, Suwandi A, Teklemariam AB, Francis N, Li L, Chinkwo KA, et al. A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents. ChemMedChem. 2026;21(20). doi:10.1002/cmdc.70534

BibTeX
@article{Woodland2026,
  author = {Woodland, Rochelle and Suwandi, Adi and Teklemariam, Awgichew Behaile and Francis, Nidhish and Li, Li and Chinkwo, Kenneth A and Baell, Jonathan B and Leaver, David J},
  title = {A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {20},
  doi = {10.1002/cmdc.70534}
}
Start for free →